Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RESTEN-MP · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| RESTEN-MP | DRUG | - |
Inclusion Criteria: 1. ≥ 18 years of age. 2. An acceptable candidate for percutaneous transluminal coronary angioplasty (PTCA), coronary artery stenting, and emergent coronary artery bypass graft (CABG). 3. Clinical evidence of ischemic heart disease or a positive functional study. 4. The target le...
RESTEN-MP is an investigational small molecule being studied for use in coronary artery disease. It was evaluated in a Phase 2 clinical trial for use in conjunction with a bare metal stent in coronary arteries, with the aim of addressing conditions such as coronary artery disease and coronary restenosis.
RESTEN-MP is being developed by Sarepta Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SRPT. The company conducted a Phase 2 clinical trial of this investigational drug for coronary artery disease.
RESTEN-MP is an investigational drug that has completed a Phase 2 clinical trial. It is not approved by the FDA and remains in clinical development. The completed trial was an uncontrolled study that enrolled 50 participants in Germany.
RESTEN-MP has been studied in one completed Phase 2 clinical trial, identified as NCT00248066. The trial, titled 'Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries,' enrolled 50 participants with coronary artery disease and coronary restenosis in Germany.
RESTEN-MP is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial for coronary artery disease. The trial was not randomized, double-blind, or controlled, and it remains in clinical development.